



**Safety
Pharmacology
Society**



Review Seizure/Convulsion Review Abuse Liability

Mary Jeanne Kallman PhD, DSP
Director Global Nonclinical Neuroscience
Covance Laboratories

WEBINAR



Facts About Seizure/Convulsion

- FDA considers convulsion an “Adverse Effect” - 10 X Margin
- Convulsion refers to the overt behavioral event while seizure refers to the electrical changes in brain (Behavioral false positives). EEG required to corroborate behavioral report
- EEG is a multi-unit recording
- EEG is the translatable clinical measure
- Usually an issue resolution endpoint
- Therapeutic compounds with seizure liability at clinical doses
- Need clinical testing plan – including subject exclusion, understanding therapeutic population, monitoring



Different Applications for Seizure Liability/EEG Testing

- Screening for efficacy
 - Treatment of epilepsy
 - Treatment of sleep disorders (sleep onset, sleep duration, % REM)
- Qualification of normal EEG activity (absence of spiking for animals assigned to tox studies)
- Screening for compound specific safety
 - Verification of observational report of convulsion (concordance of convulsion and seizure)
 - Identification of NOAEL (identification of no-effect dose)
 - ***Translational/Issue Resolution study¹**



Models For Testing

- **Efficacy Models** – Kindling, PTZ or other convulsion - precipitated models (Racine scale, observation, actual EEG recording)
- **Screening Animals for Tox Studies, NOAEL Identification and Concordance Assessments** - Typically acute EEG recordings from animals in a sling or chair with surface or needle electrodes. No surgery required
- **Translational/Issue Resolution Studies** – Continuous EEG with observation and video/ surgical implantation of electrodes for recording



Differences Between Acute and Chronic EEG Recordings

Acute Recordings

- No surgical implantation
- No mapping of sites
- Restrained animal
- Short duration recording
- Identification of seizure activity/spiking no pharmaco-EEG or staging qEEG
- More diagnostic rather than time expansive

Chronic Recordings

- Surgical implantation – surface or deep electrodes
- Can map sites
- No restraint
- 24/7 up to 3 months or more
- Identification of seizure activity/spiking, pharmaco-EEG, staging, and qEEG
- Focus on time expansive recordings




Rodent Capabilities

- Convulsive Liability (PTZ Infusion)
 - Infusion pumps deliver 10 mg/mL PTZ at a constant rate of 0.5 mL/minute until a clonic convulsion is noted in the animal or for a maximum of four minutes
 - The following formula is used to convert infusion time to mg/kg dose of PTZ administered:

$$\text{mg/kg PTZ} = \frac{(\text{Infusion time}) (\text{mL/min}) (\text{mg PTZ/mL})}{(1000\text{g})}$$

(60 seconds) (Animal weight in g)





Telemetric EEG and EMG Assessment





- Rat and Dog Animal Models

Non-tethered telemetrized animals ensure high quality behavioral data

- Continuous 24-hour data collection with concomitant video recording to corroborate EEG and EMG events indicative of seizure or convulsion across the animal's circadian cycle
- Qualitative and quantitative assessment, including spectral analysis if valuable
- Preclinical EEG analysis provides a description of the progression to seizure across time with repetitive dosing of a compound that can be applied to clinical testing



Safety Pharmacology Society



WEBINAR



**Safety
Pharmacology
Society**



Review Abuse Liability

WEBINAR



Controlled Substance Staff (CSS) at FDA

Dedicated group that serves as the CDER, FDA and DHHS focus for activities regarding drug scheduling, abuse and dependence

CSS

- Dedicated group within FDA

- Michael Klein PhD (Director)
- Silvia Calderon PhD (Team Leader)
- Lori Love MD PhD
- Katherine Bonson PhD
- James Hunter RPh, MPH
- Morine Moody
- Sandra Saltz

- Writes the 8-factor analyses (recommendation to DEA for new drugs)
- Serves as FDA and CDER liaison role to various components of government
- Provides consultation to other FDA centers regarding abuse liability assessment and drug scheduling matters
- Performs protocol reviews concerning pre-clinical and clinical protocols



Neuroscience compounds or CNS active compounds in Phase 2

- Centrally acting
- Properties that are likely to lead to misuse
 - PK parameters (short duration of action)
 - Solubility
 - High threshold for adverse toxicity
- Continued, prolonged or excessive use leads to tolerance or dose escalation
- Capable of producing dependence
- FDA Draft Guidance for Assessment of Abuse Potential of Drugs (2010)

High Priority Indications

- Pain • Psychiatry • ADHD • Migraine • Cognitive Enhancer • Antiepileptic • Anxiolytics
- Dependence treatment • Hypnotic/Sedative • Obesity • Muscle Atrophy



Drug Classes Historically Associated with Abuse Liability and Currently Scheduled by DEA

- Opioids
- Sedative hypnotics
- Cocaine, amphetamine and other CNS stimulants
- Hallucinogens, phencyclidine and similar agents
- Cannabinoids (marijuana and related compounds)
- Nicotine-like drugs
- Chemical precursors of controlled substances
- Anabolic steroids

Drug Scheduling Process

- 1** Generation of preclinical and clinical data (industry)
- 2** Drafting of 8-Factor Analysis (industry) and finalization by FDA
- 3** FDA makes scientific assessment and recommends initial schedule to DEA
- 4** DEA schedules the new drug




Approach for Identification of CNS Activity


- Binding Assays
 - Neurotransmitters historically associated with abuse potential include dopamine, norepinephrine, serotonin, GABA, nicotinic acetylcholine, opioid, NMDA, and cannabinoid receptors
 - Novel mechanism -- Full binding profile would be expected
- Routine Assays
 - Locomotor activity, Irwin, seizure activity, microdialysis, electrophysiology, brain imaging

***Question – Does the compound or a metabolite
(10% plasma level of parent) reach the CNS?***

Revised: Preclinical Flow Chart



Preclinical Flow Chart: EMEA Guideline 2006





Safety Pharmacology Society

Designs are tailored to the specific activity of the compound of interest. Typically these studies would be conducted in rodents as follows. PK determinations for the test compound can be verified

Drug Dependence Study

Repeated dosing for 2-4 weeks and evaluate signs of withdrawal from drug – including clinical signs, body weights, food intake, and other relevant assessments possible

Drug Discrimination Study

Train rats to discriminate training compound from vehicle in two-lever drug discrimination FR-10 paradigm. Conduct generalization dose response for training drug and new novel compound of interest

Self Administration Study

Rats are trained to self-administer a prototypical compound (i.e., cocaine or other compound) intravenous and then tested to determine if the new novel compound of interest will substitute in self-administration

WEBINAR




Drug Dependence

- Dependence phase (typically 2 weeks): test article administration daily
- Withdrawal phase (typically 1 week): no test article administration
- Optional Assessments
 - Filmed or Live Clinical Observations
 - Body Weights
 - Food Consumption
 - Body Temperature
 - Locomotor Activity

Clinical Observations on Ethanol Withdrawal in Male F-344 Rats Given BioServ® Control or Ethanol Liquid Diet for 14 Days


Observations	N = No behavioral change noted ↑A = Increased activity ↓A = Decreased activity ↑RA = Increased reactivity ↑RE = Increased response to stimulus ARG = Aggressive to handler FL SP = Front leg splay	HG = Hopping gait SET = Straub tail RH = Rough haircoat SL GA = Slight ataxia SL TCON = Slight continuous tremors ↓SE = decrease skin elasticity	MOD TCON = Moderate continuous tremors TH = Animal appears thin TIM = Intermittent tremor V = Increased vocalization WOT = Walking on toes CL = clonic seizure SV↑RA = severe increased reactivity	
Observation Study Day/Time Point				
	Day 14 Prior to withdrawal (Approx 7:30 AM)	Day 14 Approx 2 hr withdrawal	Day 14 Approx 4 hr withdrawal	Day 14 Approx 8 hr withdrawal
5.0% Ethanol Liquid Diet				
	SL TCON-8 MOD TCON-1 RH-4 TH-1 ↓A-11	SL TCON-7 MOD TCON-4 TIM-1 SET-1 ↑RE-2 RH-3 TH-1 V-2 ↓A-4 ↓SE-2	MOD TCON-12 SET-8 ↑RE-5 WOT-2 RH-3 V-3 TH-1 ↓SE-2	SL TCON-2 MOD TCON-5 CL-1 SET-5 AGH-3 ↑RA-6 ↑RE-1 ↑A-3 V-1

Rodent Ethanol Dependence Mean Body Weights




Drug Discrimination

- Rats are trained to discriminate between a known reinforcing compound (CNS reference compound) and vehicle by pressing the lever associated with each condition to receive a food reward
 - Test articles are substituted for the CNS reference compound
 - Test articles that elicit a response similar the CNS reference compound may have abuse liability



Amphetamine (0.3 mg/kg SC) Drug Discrimination



Self Administration

- Rats are trained to self administer a known reinforcing compound (CNS reference compound)
- Test articles are substituted for the CNS reference compound and number of injections and rates of responding are compared to reference compounds





Figure courtesy of Tom Hudzik





Important Design Parameters for Abuse Liability Studies

- Species Selection – Rat is default
- Route of Administration – Dependence Oral, Drug Discrimination IP, Self-Administration – IV
- If IV administration not possible then consider other route or Conditioned Place Conditioning
- Dose – highest dose must produce comparable blood level to human tmax blood level at the highest therapeutic dose
- Comparator Compounds – Positive Controls, Negative Controls not required

Information in 8-Factor Analysis

1. Drug's actual or relative potential for abuse
2. *Scientific evidence of the drug's pharmacological effects
3. *The state of current scientific knowledge regarding the substance
4. It's history and current pattern of abuse
5. The scope, duration, and significance of abuse
6. What, if any, risk there is to the public health
7. *The drug's psychic or physiological dependence liability
8. Whether the substance is an immediate precursor of a substance already controlled

*Sections requiring details of preclinical data for final scheduling decision by Drug Enforcement Agency (DEA)